Risk factors, survival, and impact of prophylaxis length in cytomegalovirus‐seropositive lung transplant recipients: A prospective, observational, multicenter study
Authors:
- 9 May 2017
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 19 (3)
Abstract
Background: The optimal length of cytomegalovirus (CMV) prophylaxis in lung transplantation according to CMV serostatus is not well established.Methods: We have performed a prospective, observational, multicenter study to determine the incidence of CMV infection and disease in 92 CMV‐seropositive lung transplant recipients (LTR), their related outcomes and risk factors, and the impact of prophylaxis length.Results: At 18 months post transplantation, 37 patients (40%) developed CMV infection (23 [25%]) or disease (14 [15.2%]). Overall mortality was higher in patients with CMV disease (64.3% vs 10.2%; P<.001), but only one patient died from CMV disease. In the multivariate analysis, CMV disease was an independent death risk factor (odds ratio [OR] 18.214, 95% confidence interval [CI] 4.120‐80.527; P<.001). CMV disease incidence was higher in patients with 90‐day prophylaxis than in those with 180‐day prophylaxis (31.3% vs 11.8%; P=.049). Prophylaxis length was an independent risk factor for CMV disease (OR 4.974, 95% CI 1.231‐20.094; P=.024). Sixteen patients withdrew from prophylaxis because of adverse events.Conclusion: CMV infection and disease in CMV‐seropositive LTR remain frequent despite current prophylaxis. CMV disease increases mortality, whereas 180‐day prophylaxis reduces the incidence of CMV disease.Keywords
Funding Information
- Roche Pharma Spain
This publication has 59 references indexed in Scilit:
- Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donorsTransfusion, 2013
- Granulocyte Colony-Stimulating Factor Therapy Is Associated With a Reduced Incidence of Acute Rejection Episodes or Allograft Vasculopathy in Heart Transplant RecipientsTransplantation Proceedings, 2013
- Cytomegalovirus in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patientsDrug Design, Development and Therapy, 2012
- GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patientsEnfermedades Infecciosas y Microbiología Clínica, 2011
- A review of bronchiolitis obliterans syndrome and therapeutic strategiesJournal of Cardiothoracic Surgery, 2011
- Cytomegalovirus Pneumonitis Is a Risk for Bronchiolitis Obliterans Syndrome in Lung TransplantationAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Ganciclovir for Cytomegalovirus: a Call for Indefinite Prophylaxis in Lung TransplantationThe Journal of Heart and Lung Transplantation, 2008
- Ganciclovir/Valganciclovir Prophylaxis Decreases Cytomegalovirus-Related Events and Bronchiolitis Obliterans Syndrome after Lung TransplantationClinical Infectious Diseases, 2008
- Chronic Allograft Rejection (Obliterative Bronchiolitis)Seminars in Respiratory and Critical Care Medicine, 2001